UY35989A - Uso de paricalcitol en el tratamiento de la anemia inflamatoria - Google Patents
Uso de paricalcitol en el tratamiento de la anemia inflamatoriaInfo
- Publication number
- UY35989A UY35989A UY35989A UY35989A UY35989A UY 35989 A UY35989 A UY 35989A UY 35989 A UY35989 A UY 35989A UY 35989 A UY35989 A UY 35989A UY 35989 A UY35989 A UY 35989A
- Authority
- UY
- Uruguay
- Prior art keywords
- paricalcitol
- treatment
- inflammatory anemia
- stimulating agents
- erythropoiesis stimulating
- Prior art date
Links
- 229960000987 paricalcitol Drugs 0.000 title abstract 4
- BPKAHTKRCLCHEA-UBFJEZKGSA-N paricalcitol Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@@H](\C=C\[C@H](C)C(C)(C)O)C)=C\C=C1C[C@@H](O)C[C@H](O)C1 BPKAHTKRCLCHEA-UBFJEZKGSA-N 0.000 title abstract 4
- 208000007502 anemia Diseases 0.000 title abstract 3
- 230000002757 inflammatory effect Effects 0.000 title abstract 3
- 239000003173 antianemic agent Substances 0.000 abstract 3
- 229940125367 erythropoiesis stimulating agent Drugs 0.000 abstract 3
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 abstract 2
- 102000003951 Erythropoietin Human genes 0.000 abstract 1
- 108090000394 Erythropoietin Proteins 0.000 abstract 1
- 229930003316 Vitamin D Natural products 0.000 abstract 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940105423 erythropoietin Drugs 0.000 abstract 1
- 229910052742 iron Inorganic materials 0.000 abstract 1
- 230000007170 pathology Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 1
- 235000019166 vitamin D Nutrition 0.000 abstract 1
- 239000011710 vitamin D Substances 0.000 abstract 1
- 150000003710 vitamin D derivatives Chemical class 0.000 abstract 1
- 229940046008 vitamin d Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES201430177A ES2472040B1 (es) | 2014-02-11 | 2014-02-11 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY35989A true UY35989A (es) | 2015-03-27 |
Family
ID=51205045
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY35989A UY35989A (es) | 2014-02-11 | 2015-02-10 | Uso de paricalcitol en el tratamiento de la anemia inflamatoria |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11464791B2 (enExample) |
| EP (1) | EP3104872B1 (enExample) |
| JP (1) | JP2017512753A (enExample) |
| KR (1) | KR20160113664A (enExample) |
| CN (1) | CN106061498B (enExample) |
| AR (1) | AR099330A1 (enExample) |
| AU (1) | AU2015217956B2 (enExample) |
| CA (1) | CA2938057A1 (enExample) |
| DK (1) | DK3104872T3 (enExample) |
| ES (2) | ES2472040B1 (enExample) |
| IL (1) | IL247207B (enExample) |
| MX (1) | MX365096B (enExample) |
| PT (1) | PT3104872T (enExample) |
| RU (1) | RU2016131412A (enExample) |
| UY (1) | UY35989A (enExample) |
| WO (1) | WO2015121022A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102504090B1 (ko) * | 2020-08-05 | 2023-02-24 | 경상국립대학교병원 | 조영제-유발 신독성 예방 또는 치료용 약학 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004062620A2 (en) * | 2003-01-13 | 2004-07-29 | Cedars-Sinai Medical Center | Paricalcitol as a chemotherapeutic agent |
| CA2563874A1 (en) * | 2004-04-23 | 2005-11-03 | Cambridge Antibody Technology Limited | Erythropoietin protein variants |
| CN101610782A (zh) * | 2007-01-10 | 2009-12-23 | 爱迪生药物公司 | 使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱 |
| CN102772364B (zh) * | 2011-05-13 | 2015-12-02 | 重庆华邦制药有限公司 | 帕立骨化醇的脂肪乳及其制剂和制备方法 |
-
2014
- 2014-02-11 ES ES201430177A patent/ES2472040B1/es not_active Expired - Fee Related
-
2015
- 2015-01-16 CN CN201580007824.4A patent/CN106061498B/zh active Active
- 2015-01-16 US US15/117,896 patent/US11464791B2/en active Active
- 2015-01-16 CA CA2938057A patent/CA2938057A1/en not_active Abandoned
- 2015-01-16 RU RU2016131412A patent/RU2016131412A/ru unknown
- 2015-01-16 ES ES15702156T patent/ES2728158T3/es active Active
- 2015-01-16 DK DK15702156.9T patent/DK3104872T3/da active
- 2015-01-16 EP EP15702156.9A patent/EP3104872B1/en active Active
- 2015-01-16 PT PT15702156T patent/PT3104872T/pt unknown
- 2015-01-16 KR KR1020167023202A patent/KR20160113664A/ko not_active Ceased
- 2015-01-16 AU AU2015217956A patent/AU2015217956B2/en active Active
- 2015-01-16 JP JP2016552329A patent/JP2017512753A/ja active Pending
- 2015-01-16 WO PCT/EP2015/050817 patent/WO2015121022A1/en not_active Ceased
- 2015-01-16 MX MX2016010104A patent/MX365096B/es active IP Right Grant
- 2015-02-10 UY UY35989A patent/UY35989A/es not_active Application Discontinuation
- 2015-02-10 AR ARP150100380A patent/AR099330A1/es unknown
-
2016
- 2016-08-10 IL IL247207A patent/IL247207B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2472040R1 (es) | 2014-09-18 |
| IL247207B (en) | 2020-02-27 |
| US11464791B2 (en) | 2022-10-11 |
| AU2015217956B2 (en) | 2019-04-04 |
| ES2728158T3 (es) | 2019-10-22 |
| US20160367571A1 (en) | 2016-12-22 |
| ES2472040B1 (es) | 2015-07-01 |
| RU2016131412A (ru) | 2018-03-15 |
| CN106061498A (zh) | 2016-10-26 |
| MX365096B (es) | 2019-05-22 |
| JP2017512753A (ja) | 2017-05-25 |
| CA2938057A1 (en) | 2015-08-20 |
| DK3104872T3 (da) | 2019-06-17 |
| ES2472040A2 (es) | 2014-06-27 |
| KR20160113664A (ko) | 2016-09-30 |
| CN106061498B (zh) | 2019-12-06 |
| AR099330A1 (es) | 2016-07-13 |
| IL247207A0 (en) | 2016-09-29 |
| PT3104872T (pt) | 2019-06-11 |
| MX2016010104A (es) | 2017-01-06 |
| WO2015121022A1 (en) | 2015-08-20 |
| EP3104872A1 (en) | 2016-12-21 |
| AU2015217956A1 (en) | 2016-08-25 |
| EP3104872B1 (en) | 2019-03-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018001685A1 (es) | Compuestos heterociclicos como inmuno moduladores. | |
| MX2018003388A (es) | Agonistas del receptor farnesoide x y usos de los mismos. | |
| ECSP19052302A (es) | Derivados de benzooxazol como inmunomoduladores | |
| ECSP20046463A (es) | Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas | |
| MX382033B (es) | Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma. | |
| MX2016010213A (es) | Formulaciones farmaceuticas novedosas. | |
| UY35916A (es) | Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio | |
| MX386547B (es) | Combinación de un antagonista con muerte programada 1 (pd-1) y eribulina para el tratamiento de cáncer. | |
| CL2015002767A1 (es) | Compuestos terapéuticos y composiciones | |
| ES3057783T3 (en) | Combinations of lsd1 inhibitors for use in the treatment of neoplastic diseases | |
| UY34657A (es) | ?derivados macrocíclicos para el tratamiento de enfermedades?. | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| MX2019003397A (es) | Metodos para tratar trastornos mitocondriales y metabolicos. | |
| CR20180228A (es) | Terapia adjunta con 25-hidroxi vitamina d y articulos de la misma | |
| MX2018004664A (es) | Antagonistas de ep4. | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| CL2018003338A1 (es) | Formulaciones inyectables fisiológicamente balanceadas de fosnetupitant. | |
| UY36117A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas. | |
| ECSP16086247A (es) | (s)-pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| CL2016000884A1 (es) | Derivados de piperazina y su uso como medicamento. | |
| UY36732A (es) | Piridin pirazinonas novedosas como inhibidores de bromodominios de la familia bet | |
| MX2017009608A (es) | Compuestos anticancerigenos. | |
| ECSP16086232A (es) | (r) -pirlindole y sus sales farmacéuticamente aceptables para uso en medicina | |
| MX384637B (es) | Compuestos oxadiazoespíricos para el tratamiento del abuso y la adicción a las drogas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20220610 |